Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 10/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.34 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6729001 | 0.92 | RPS6KA3 (0.39) | RPS6KA3PTGS2AAK1CYP17A1DGAT2 | |
| SCHEMBL6718626 | 0.85 | RPS6KA3 (0.45) | RPS6KA3DGAT2 | |
| SCHEMBL6722648 | 0.85 | RPS6KA3 (0.45) | RPS6KA3PTGS2PTGS1CYP17A1 | |
| SCHEMBL6725964 | 0.85 | RPS6KA3 (0.45) | RPS6KA3PTGS2PTGS1 | |
| SCHEMBL6718754 | 0.84 | RPS6KA3 (0.41) | RPS6KA3PTGS2AAK1CYP17A1 | |
| SCHEMBL6725948 | 0.84 | RPS6KA3 (0.46) | RPS6KA3PTGS2CYP17A1 | |
| SCHEMBL7537413 | 0.83 | PTGS2 (0.42) | RPS6KA3FFAR1FFAR4SCN5APTGS2 | |
| SCHEMBL6736657 | 0.83 | RPS6KA3 (0.43) | RPS6KA3FFAR1FFAR4SCN5APTGS2 | |
| SCHEMBL6729663 | 0.82 | RPS6KA3 (0.47) | RPS6KA3DGAT2 | |
| SCHEMBL6844127 | 0.82 | RPS6KA3 (0.42) | RPS6KA3FFAR1FFAR4SCN5APTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, PTGES2, FPR1 | RPS6KA3 972/4885FFAR1 70/4885FFAR4 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.